Revolution Medicines (RVMD) just saw its stock crater 17% after reports surfaced that Merck has officially pulled the plug on its rumored $30 billion takeover. After weeks of intense M&A hype and a 50% rally, the "takeover premium" is evaporating, leaving investors with a classic case of "selling the lack of news."

In this episode, we break down:

• The Valuation Standoff: Why Merck walked away from the table and why AbbVie isn't coming to the rescue.

• The "Zero Revenue" Reality: How a company burning $1 billion a year maintains a massive $1.9 billion cash cushion.

• The Science vs. The Hype: Why the upcoming Phase 3 data for daraxonrasib might be the  ...